Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. May 16, 2018. Ricki Chase.

Executive Summary

US FDA has set up an email inbox to accept inquiries from device-makers about facility inspections under its year-old "program alignment" audit scheme. See what former FDA investigations branch director (now consultant) Ricki Chase said about it here.

"Firms are always afraid to ask questions, because if the question indicates that maybe there's an issue, they're worried that they're going to be inspected. But that's just not how it works. The agency is trying to be more transparent and more user-friendly, and part of being more user-friendly is to establish this general question inbox [[email protected]] where you can send a question, and somebody will get back to you with a reference or a resource. Or sometimes they'll say, 'Give me a call and we can discuss it.'" –Ricki Chase, compliance practice director, Lachman Consultant Services

Click here for a free trial of Medtech Insight

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel